Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895758 | 0.79 | KDM4E (0.49) | ALKBH2EGLN1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL30796754 | 0.78 | GRM5 (0.66) | ALKBH2EGLN1GRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL3918642 | 0.78 | GRM5 (0.66) | ALKBH2EGLN1GRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL16547471 | 0.78 | ALDH1A1 (0.49) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL5668701 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4SMN1; SMN2RAB9A | |
| SCHEMBL2159890 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4SMN1; SMN2NPC1 | |
| SCHEMBL3923413 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4SMN1; SMN2GRM5 | |
| SCHEMBL15671484 | 0.78 | EGLN1 (0.57) | ALKBH2EGLN1GRM4SMN1; SMN2GRM5 | |
| SCHEMBL20658802 | 0.78 | ALKBH2 (0.57) | ALKBH2EGLN1GRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL23872054 | 0.77 | ALKBH2 (0.53) | ALKBH2EGLN1GRM4SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-0846113-B1 | 1-(PYRIDYL)-PYRAZOLS AND THEIR USE AS HERBICIDES | BASF AG (DE) | 2003-01-29 | — | — | EP | disclosed |
| EP-0759429-B1 | Substituted trifluormethylpyridines useful as intermediates for herbicidal 1-(pyridyl)-pyrazoles | BASF AG (DE) | 2001-10-24 | — | — | EP | disclosed |
| EP-0846113-A1 | 1-(PYRIDYL)-PYRAZOLS AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997007114-A1 | 1-(PYRIDYL)-PYRAZOLS AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-27 | — | — | WO | disclosed |
| EP-0759429-A1 | Substituted trifluormethylpyridines useful as intermediates for herbicidal 1-(pyridyl)-pyrazoles | BASF Aktiengesellschaft (DE) | 1997-02-26 | — | — | EP | disclosed |
| EP-0366329-B1 | Halogeno-4-methylpyrazoles and process for preparing the same | NISSAN CHEMICAL IND LTD (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5220028-A | Halogeno-4-methylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0366328-B1 | PROCESS FOR PREPARING 4-METHYLPYRAZOLES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1993-05-19 | — | — | EP | disclosed |
| EP-0366329-A1 | Halogeno-4-methylpyrazoles and process for preparing the same | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366328-A1 | Process for preparing 4-methylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | ALKBH2 4823/4885EGLN1 239/4885GRM4 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.